Cyclodextrin derivatives as anti-infectives

Current Opinion in Pharmacology

Volumn 13, Issue 5, 2013, Pages 717-725

  Karginov, Vladimir A ^a  

^a Innovative Biologics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CYCLODEXTRIN DERIVATIVE; ALPHA HEMOLYSIN; ANTHRAX TOXIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; BETA CYCLODEXTRIN DERIVATIVE; CELL SURFACE RECEPTOR; CIPROFLOXACIN; CYCLODEXTRIN DERIVATIVE; EDEMA TOXIN; EPSILON TOXIN; GAMMA CYCLODEXTRIN DERIVATIVE; LETHAL TOXIN; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PORE FORMING CYTOTOXIC PROTEIN; RAXIBACUMAB; UNCLASSIFIED DRUG;

ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; CELL MEMBRANE TRANSPORT; CELL PROTECTION; CLOSTRIDIUM BOTULINUM; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM PERFRINGENS; DRUG BINDING SITE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG TARGETING; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACILLUS ANTHRACIS; BACTERIAL TOXINS; CLOSTRIDIUM PERFRINGENS; CYCLODEXTRINS; HUMANS; STAPHYLOCOCCUS AUREUS;

EID: 84893004916     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.08.007     Document Type: Review

References (54)

1. Szejtli J: Introduction and general overview of cyclodextrin chemistry. Chem Rev 1998, 98: 1743-1753. (Pubitemid 128633435)
2. Stella VJ, He Q: Cyclodextrins. Toxicol Pathol 2008, 36: 30-42.
3. Loftsson T, Brewster ME: Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol 2010, 62: 1607-1621.
4. Uekama K, Hirayama F, Irie T: Cyclodextrin drug carrier systems. Chem Rev 1998, 98: 2045-2076. (Pubitemid 128633447)
5. Khan AR, Forgo P, Stine KJ, D'Souza VT: Methods for selective modification of cyclodextrins. Chem Rev 1998, 98: 1977-1996.
6. Aleem O, Kuchekar B, Pore Y, Late S: Effect of beta-cyclodextrin and hydroxypropyl beta-cyclodextrin complexation on physicochemical properties and antimicrobial activity of cefdinir. J Pharm Biomed Anal 2008, 47: 535-540.
7. Song W, Yu X, Wang S, Blasier R, Markel DC, Mao G, Shi T, Ren W: Cyclodextrin-erythromycin complexes as a drug delivery device for orthopedic application. Int J Nanomed. 2011, 6: 3173-3186.
8. Karginov VA, Nestorovich EM, Moayeri M, Leppla SH, Bezrukov SM: Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design. Proc Natl Acad Sci U S A 2005, 102: 15075-15080. (Pubitemid 41513337)
9. Karginov VA, Yohannes A, Robinson TM, Fahmi NE, Alibek K, Hecht SM: b-Cyclodextrin derivatives that inhibit anthrax lethal toxin. Bioorg Med Chem 2006, 14: 33-40. (Pubitemid 41635466)
10. Karginov VA, Nestorovich EM, Yohannes A, Robinson TM, Fahmi NE, Schmidtmann F, Hecht SM, Bezrukov SM: Search for cyclodextrin-based inhibitors of anthrax toxins: synthesis, structural features, and relative activities. Antimicrob Agents Chemother 2006, 50: 3740-3753. (Pubitemid 44684889)
11. Karginov VA, Nestorovich EM, Schmidtmann F, Robinson TM, Yohannes A, Fahmi NE, Bezrukov SM, Hecht SM: Inhibition of S. aureus a-hemolysin and B. anthracis lethal toxin by b-cyclodextrin derivatives. Bioorg Med Chem 2007, 15: 5424-5431. (Pubitemid 46963000)
12. Backer MV, Patel V, Jehnings BT, Claffey KP, Karginov VA, Backer JM: Inhibition of anthrax protective antigen outside and inside the targeted cell. Antimicrob Agents Chemother 2006, 1: 245-251. (Pubitemid 46047713)
13. Bezrukov SM, Liu X, Karginov VA, Wein AN, Leppla SH, Popoff MR, Barth H, Nestorovich EM: Interactions of high-affinity cationic blockers with the translocation pores of B. anthracis, C. botulinum, and C. perfringens binary toxins. Biophys J 2012, 103: 1208-1217.
14. Moayeri M, Robinson TM, Leppla SH, Karginov VA: In vivo efficacy of b-cyclodextrin derivatives against anthrax lethal toxin. Antimicrob Agents Chemother 2008, 52: 2239-2241. (Pubitemid 351758567)
15. Ragle BE, Karginov VA, Wardenburg JB: Prevention and treatment of Staphylococcus aureus pneumonia with a b-cyclodextrin derivative. Antimicrob Agents Chemother 2010, 54: 298-304.
16. Nestorovich EM, Karginov VA, Berezhkovskii AM, Bezrukov SM: Blockage of anthrax PA63 pore by a multi-charged high-affinity toxin inhibitor. Biophys J 2010, 99: 134-143.
17. Nestorovich EM, Karginov VA, Popoff MR, Bezrukov SM, Barth H: Tailor-made b-cyclodextrin derivative blocks the translocation pores of binary exotoxins from Clostridium botulinum and Clostridium perfringens and protects mammalian cells from intoxication. PLoS ONE 2011, 6:e23927.
18. Nestorovich EM, Karginov VA, Berezhkovskii AM, Parsegian VA, Bezrukov SM: Kinetics and thermodynamics of binding reactions as exemplified by anthrax channel blockage with a cationic cyclodextrin derivative. Proc Natl Acad Sci U S A 2012, 109: 18453-18458.
19. Díaz-Moscoso A, Méndez-Ardoy A, Ortega-Caballero F, Benito JM, Ortiz Mellet C, Defaye J, Robinson TM, Yohannes A, Karginov VA, García Fernández JM: Symmetry xomplementarity-guided design of anthrax toxin inhibitors based on b-cyclodextrin: synthesis and relative activities of face-selective functionalized polycationic clusters. ChemMedChem 2011, 6: 181-192.
20. Yannakopoulou K, Jicsinszky L, Aggelidou C, Mourtzis N, Robinson TM, Yohannes A, Nestorovich EM, Bezrukov SM, Karginov VA: Symmetry requirements for the effective blocking of pore-forming toxins: comparative study with a-, b- and g-cyclodextrin derivatives. Antimicrob Agents Chemother 2011, 55: 3594-3597.
21. Alksne LE, Projan SJ: Bacterial virulence as a target for antimicrobial chemotherapy. Curr Opin Biotechnol 2000, 6: 625-636.
22. Bischofberger M, Iacovache I, van der Goot FG: Pathogenic pore-forming proteins: function and host response. Cell Host Microbe 2012, 12: 266-275.
23. Nieva JL, Madan V, Carrasco L: Viroporins: structure and biological functions. Nat Rev Microbiol 2012, 10: 563-574.
24. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH: The molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985, 4: 3021-3024.
25. Lamb RA, Zebedee SL, Richardson CD: Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 1985, 40: 627-633. (Pubitemid 15076578)
26. Li Y, Sherer K, Cui X, Eichacker PQ: New insights into the pathogenesis and treatment of anthrax toxin-induced shock. Expert Opin Biol Ther 2007, 7: 843-854. (Pubitemid 46954431)
27. Young JA, Collier RJ: Anthrax toxin: receptor-binding, internalization, pore formation, and translocation. Annu Rev Biochem 2007, 76: 243-265.
28. Moayeri M, Leppla SH: Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol Aspects Med 2009, 30: 439-455.
29. Schneemann A, Manchester M: Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax. Future Microbiol 2009, 4: 35-43.
30. Kintzer KF, Thoren KL, Sterling HJ, Dong KC, Feld GK, Tang II, Zhang TT, Williams ER, Berger JM, Krantz BA: The protective antigen component of anthrax toxin forms functional octameric complexes. J Mol Biol 2009, 392: 614-629.
31. Krantz BA, Melnyk RA, Zhang S, Juris SJ, Lacy DB, Wu Z, Finkelstein A, Collier RJ: A phenylalanine clamp catalyzes protein translocation through the anthrax toxin pore. Science 2005, 309: 777-781. (Pubitemid 41077325)
32. Karginova E, Robinson T, Karginov V: Pharmacokinetic evaluation of cyclodextrin derivatives using an ELISA based assay. 16th International Cyclodextrins Symposium; Tianjin, China, May 6-10: 2012.
33. Joshi A, Kate S, Poon V, Mondal D, Boggara MB, Saraph A, Martin JT, McAlpine R, Day R, Garcia AE, Mogridge J, Kane RS: Structure-based design of a heptavalent anthrax toxin inhibitor. Biomacromolecules 2011, 12: 791-796.
34. Lowy FD: Staphylococcus aureus infections. N Engl J Med 1998, 339: 520-532.
35. Chambers HF, DeLeo FR: Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009, 7: 2464-2474.
36. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF: Community- associated meticillin-resistant Staphylococcus aureus. Lancet 2010, 375: 1557-1568.
37. Otto M: MRSA virulence and spread. Cell Microbiol 2012, 14: 1513-1521.
38. Vandenesch F, Lina G, Henry T: Staphylococcus aureus hemolysins, bi-component leukocidins, and cytolytic peptides: a redundant arsenal of membrane-damaging virulence factors? Front Cell Infect Microbiol 2012, 2:12.
39. Patel AH, Nowlan P, Weavers ED, Foster T: Virulence of protein A-deficient and alpha-toxin-deficient mutants of Staphylococcus aureus isolated by allele replacement. Infect Immun 1987, 55: 3103-3110. (Pubitemid 18008284)
40. Ji Y, Marra A, Rosenberg M, Woodnutt G: Regulated antisense RNA eliminates alpha-toxin virulence in Staphylococcus aureus infection. J Bacteriol 1999, 181: 6585-6590. (Pubitemid 29517970)
41. Bubeck-Wardenburg J, Patel RJ, Schneewind O: Surface proteins and exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia. Infect Immun 2007, 75: 1040-1044. (Pubitemid 46203470)
42. Bubeck-Wardenburg J, Schneewind O: Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 2008, 205: 287-294. (Pubitemid 351281594)
43. Menestrina G, Serra MD, Prévost G: Mode of action of beta-barrel pore-forming toxins of the staphylococcal alpha-hemolysin family. Toxicon 2001, 39: 1661-1672. (Pubitemid 32786998)
44. Montoya M, Gouaux E: Beta-barrel membrane protein folding and structure viewed through the lens of alpha-hemolysin. Biochim Biophys Acta 2003, 1609: 19-27. (Pubitemid 36044061)
45. Song L, Hobaugh MR, Shustak C, Cheley S, Bayley H, Gouaux JE: Structure of staphylococcal alpha-hemolysin, a heptameric transmembrane pore. Science 1996, 274: 1859-1866. (Pubitemid 26424757)
46. Caballero AR, McCormick C, Karginov V, O'Callaghan R: Analysis of the effectiveness of three chemical inhibitors of alpha-toxin in the treatment of S. aureus experimental keratitis. World Cornea Congress VI; Boston, MA, April 7-9: 2010.
47. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, Braughton KR, Schneewind O, DeLeo FR: Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 2010, 202: 1050-1058.
48. Tkaczyk C, Hua L, Varkey R, Shi Y, Dettinger L, Woods R, Barnes A, MacGill RS, Wilson S, Chowdhury P, Stover CK, Sellman BR: Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clin Vaccine Immunol 2012, 19: 377-385.
49. Songer JG: Clostridial enteric diseases of domestic animals. Clin Microbiol Rev 1996, 9: 216-234. (Pubitemid 26124457)
50. Smedley JG 3rd, Fisher DJ, Sayeed S, Chakrabarti G, McClane BA: The enteric toxins of Clostridium perfringens. Rev Physiol Biochem Pharmacol 2004, 152: 183-204. (Pubitemid 44404364)
51. Popoff MR: Epsilon toxin: a fascinating pore-forming toxin. FEBS J 2011, 278: 4602-4615.
52. Miyata S, Minami J, Tamai E, Matsushita O, Shimamoto S, Okabe A: Clostridium perfringens epsilon-toxin forms a heptameric pore within the detergent-insoluble microdomain of Madin-Darby canine kidney cells and rat synaptosomes. J Biol Chem 2002, 277: 39463-39468. (Pubitemid 35190922)
53. Cole AR, Gibert M, Popoff M, Moss DS, Titball RW, Basak AK: Clostridium perfringens epsilon toxin shows structural similarity to the pore-forming toxin aerolysin. Nat Struct Mol Biol 2004, 11: 797-798. (Pubitemid 39014507)
54. Boley M, Robinson T, Jicsinszky L, Karginov V, Langenbach K: In-vitro inhibition of Clostridium perfringens epsilon toxin using beta-cyclodextrin derivatives provides a potential strategy for therapeutic development. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, September 9-12: 2012.